Viatris To Buy Pacira BioSciences For $1.65B
Viatris has agreed to acquire non-opioid pain treatment maker Pacira BioSciences for $1.65 billion, with Cravath Swaine & Moore LLP advising Viatris and Ashurst Perkins Coie representing Pacira, the companies said...To view the full article, register now.
Already a subscriber? Click here to view full article